Reaction
Gastrostomy Tube Site Complication reporting signals
As of the last recalculation, Gastrostomy Tube Site Complication appears in 191 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 103.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 12 | 103.5 | 103.6 |
| Palivizumab | 6 | 43.9 | 43.9 |
| Cannabidiol | 8 | 38.8 | 38.9 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 4 | 35.7 | 35.7 |
| Dornase Alfa | 6 | 34.4 | 34.4 |
| Vigabatrin | 3 | 22.8 | 22.8 |
| Pimavanserin Tartrate | 6 | 12.2 | 12.2 |